BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113:1649-1659. [PMID: 29880964 DOI: 10.1038/s41395-018-0088-6] [Cited by in Crossref: 181] [Cited by in F6Publishing: 167] [Article Influence: 45.3] [Reference Citation Analysis]
Number Citing Articles
1 Fernández-Ramos D, Lopitz-Otsoa F, Delacruz-Villar L, Bilbao J, Pagano M, Mosca L, Bizkarguenaga M, Serrano-Macia M, Azkargorta M, Iruarrizaga-Lejarreta M, Sot J, Tsvirkun D, van Liempd SM, Goni FM, Alonso C, Martínez-Chantar ML, Elortza F, Hayardeny L, Lu SC, Mato JM. Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation. World J Gastroenterol 2020; 26(34): 5101-5117 [PMID: 32982112 DOI: 10.3748/wjg.v26.i34.5101] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
2 Sharma P, Sui Z, Zhang M, Magee JC, Barman P, Patel Y, Schluger A, Walter K, Biggins SW, Cullaro G, Wong R, Lai JC, Jo J, Sinha J, VanWagner L, Verna EC. Renal Outcomes After Simultaneous Liver-Kidney Transplantation: Results from the US Multicenter Simultaneous Liver-Kidney Transplantation Consortium. Liver Transpl 2021;27:1144-53. [PMID: 33641218 DOI: 10.1002/lt.26032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Horst AK, Najjar SM, Wagener C, Tiegs G. CEACAM1 in Liver Injury, Metabolic and Immune Regulation. Int J Mol Sci 2018;19:E3110. [PMID: 30314283 DOI: 10.3390/ijms19103110] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
4 Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, Galle PR, Wörns MA, Anstee QM, Schuppan D, Schattenberg JM. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther 2018;48:1109-16. [PMID: 30288767 DOI: 10.1111/apt.14976] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
5 Klaikeaw N, Wongphoom J, Werawatganon D, Chayanupatkul M, Siriviriyakul P. Anti-inflammatory and anti-oxidant effects of aloe vera in rats with non-alcoholic steatohepatitis. World J Hepatol 2020; 12(7): 363-377 [PMID: 32821335 DOI: 10.4254/wjh.v12.i7.363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
6 Shikora SA, Edgerton C, Harris D, Buchwald H. Metabolic surgery. Current Problems in Surgery 2021. [DOI: 10.1016/j.cpsurg.2021.101059] [Reference Citation Analysis]
7 Sequeira IR, Woodhead JST, Chan A, D'Souza RF, Wan J, Hollingsworth KG, Plank LD, Cohen P, Poppitt SD, Merry TL. Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. Biochim Biophys Acta Gen Subj 2021;1865:129991. [PMID: 34419510 DOI: 10.1016/j.bbagen.2021.129991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Hu Z, Li Y, Yang Y, Yu W, Xie W, Song G, Qian Y, Song Z. Serum lipids mediate the relationship of multiple polyaromatic hydrocarbons on non-alcoholic fatty liver disease: A population-based study. Sci Total Environ 2021;780:146563. [PMID: 34030288 DOI: 10.1016/j.scitotenv.2021.146563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Silva MBDBE, Tustumi F, Dantas ACB, Miranda BCJ, Pajecki D, De-cleva R, Santo MA, Nahas SC. OBESIDADE E ESTEATOSE GRAVE: A IMPORTÂNCIA DA AVALIAÇÃO BIOQUÍMICA E ESCORES. ABCD, arq bras cir dig 2021;34:e1626. [DOI: 10.1590/0102-672020210002e1626] [Reference Citation Analysis]
10 Lopez-Lopez V, Ruiz-Manzanera JJ, Eshmuminov D, Lehmann K, Schneider M, von der Groeben M, de Angulo DR, Gajownik U, Pons JA, Sanchez-Bueno F, Robles-Campos R, Ramirez-Romero P. Are We Ready for Bariatric Surgery in a Liver Transplant Program? Obes Surg. 2020;31:1214-1222. [PMID: 33225408 DOI: 10.1007/s11695-020-05118-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Pai RK, Jairath V, Hogan M, Zou G, Adeyi OA, Anstee QM, Aqel BA, Behling C, Carey EJ, Clouston AD, Corey K, Feagan BG, Kleiner DE, Ma C, McFarlane SC, Noureddin M, Ratziu V, Valasek MA, Younossi ZM, Harrison SA, Loomba R. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology 2022. [PMID: 35332569 DOI: 10.1002/hep.32475] [Reference Citation Analysis]
12 Jiang X, Melum E. The Role of Natural Killer Cells in Nonalcoholic Steatohepatitis: An Ongoing Debate. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00220-4. [PMID: 34740615 DOI: 10.1016/j.jcmgh.2021.10.006] [Reference Citation Analysis]
13 Pita A, Kaur N, Emamaullee J, Lo M, Nguyen B, Sabour A, Tristan V, Nadim M, Genyk Y, Sher L. Outcomes of Liver Transplantation in Patients on Renal Replacement Therapy: Considerations for Simultaneous Liver Kidney Transplantation Versus Safety Net. Transplant Direct 2019;5:e490. [PMID: 31723585 DOI: 10.1097/TXD.0000000000000935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
14 Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther 2019;50:193-203. [PMID: 31246368 DOI: 10.1111/apt.15316] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
15 Lee DH, Cho EJ, Bae JS, Lee JY, Yu SJ, Kim H, Lee KB, Han JK, Choi BI. Accuracy of Two-Dimensional Shear Wave Elastography and Attenuation Imaging for Evaluation of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2021;19:797-805.e7. [PMID: 32450363 DOI: 10.1016/j.cgh.2020.05.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
16 Noureddin N, Yang JD, Alkhouri N, Noreen SM, Toll AE, Todo T, Ayoub W, Kuo A, Voidonikolas G, Kotler HG, Pelphrey MD, Durand BJ, Kosari K, Brennan TV, Kim I, Klein AS, Seki E, Nissen NN, Lu SC, Sundaram V, Noureddin M. Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004-2018 Analysis. Transplant Direct 2020;6:e612. [PMID: 33134488 DOI: 10.1097/TXD.0000000000001051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Нетяженко ВЗ, Баженова НМ. The Effect of Obesity on the State of Platelet-plasma Hemostasis in Patients with Essential Hypertension in Combination with Non-alcoholic Fatty Liver Disease. Family Medicine 2020;0:56-62. [DOI: 10.30841/2307-5112.4.2020.217657] [Reference Citation Analysis]
18 Sarkar M, Suzuki A. Reproductive Health and Nonalcoholic Fatty Liver Disease in Women: Considerations Across the Reproductive Lifespan. Clin Liver Dis (Hoboken) 2020;15:219-22. [PMID: 32617153 DOI: 10.1002/cld.955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Jung J, Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 2021;70:1946-53. [PMID: 33214165 DOI: 10.1136/gutjnl-2020-322976] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
20 Li H, Wang Q, Chen P, Zhou C, Zhang X, Chen L. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol 2021;12:788558. [PMID: 34938193 DOI: 10.3389/fphar.2021.788558] [Reference Citation Analysis]
21 Leivas G, Maraschin CK, Blume CA, Telo GH, Trindade MRM, Trindade EN, Diemen VV, Cerski CTS, Schaan BD. Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study. Obes Res Clin Pract 2021;15:461-5. [PMID: 34511367 DOI: 10.1016/j.orcp.2021.09.002] [Reference Citation Analysis]
22 Al Attar A, Antaramian A, Noureddin M. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Rev Clin Pharmacol 2021;14:457-64. [PMID: 33612037 DOI: 10.1080/17512433.2021.1894127] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Rosato V, Masarone M, Aglitti A, Persico M. The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00018] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Schuster-Gaul S, Geisler LJ, McGeough MD, Johnson CD, Zagorska A, Li L, Wree A, Barry V, Mikaelian I, Jih LJ, Papouchado BG, Budas G, Hoffman HM, Feldstein AE. ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model. JCI Insight 2020;5:123294. [PMID: 31996485 DOI: 10.1172/jci.insight.123294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
25 Aslam S, Buggs J, Melo S, Ermekbaeva A, Rogers E, Shaw R, Kumar A, Kemmer N. The Association Between Alcoholic Liver Disease and Alcohol Tax. The American Surgeon 2021;87:92-6. [DOI: 10.1177/0003134820945223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, Henry L. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020;69:564-8. [PMID: 31366455 DOI: 10.1136/gutjnl-2019-318813] [Cited by in Crossref: 149] [Cited by in F6Publishing: 114] [Article Influence: 74.5] [Reference Citation Analysis]
27 Vyhmeister R, Enestvedt CK. The Changing Liver Transplant Recipient: From Hepatitis C to Nonalcoholic Steatohepatitis and Alcohol. Clin Liver Dis 2021;25:137-55. [PMID: 33978575 DOI: 10.1016/j.cld.2020.08.012] [Reference Citation Analysis]
28 So WZ, Tan FL, Tan DJH, Ng CH, Yong JN, Syn N, Tang ASP, Wong RC, Lin W, Tan EXX, Huang DQ, Dan YY, Chew NWS, Siddiqui MS, Muthiah MD. A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. Dig Liver Dis 2021:S1590-8658(21)00851-3. [PMID: 34896025 DOI: 10.1016/j.dld.2021.11.011] [Reference Citation Analysis]
29 Milic J, Barbieri S, Gozzi L, Brigo A, Beghé B, Verduri A, Bacca E, Iadisernia V, Cuomo G, Dolci G, Yaacoub D, Aprile E, Belli M, Venuta M, Meschiari M, Sebastiani G, Clini E, Mussini C, Lonardo A, Guaraldi G, Raggi P. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis 2022;9:ofac003. [PMID: 35146047 DOI: 10.1093/ofid/ofac003] [Reference Citation Analysis]
30 de Brito E Silva MB, Tustumi F, de Miranda Neto AA, Dantas ACB, Santo MA, Cecconello I. Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis. Obes Surg 2021;31:2762-72. [PMID: 33846949 DOI: 10.1007/s11695-021-05412-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
31 Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, Lonardo A, Marietta M, Dentali F, Cioni G. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Adv Ther 2020;37:1910-32. [PMID: 32285340 DOI: 10.1007/s12325-020-01307-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
32 Spinosa M, Stine JG. Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State? Curr Pharm Des 2020;26:1036-44. [PMID: 32003679 DOI: 10.2174/1381612826666200131101553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
33 Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D. Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int. 2020;40:736-750. [PMID: 31997561 DOI: 10.1111/liv.14390] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
34 Noureddin M, Ntanios F, Malhotra D, Hoover K, Emir B, McLeod E, Alkhouri N. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. Hepatol Commun 2022. [PMID: 35365931 DOI: 10.1002/hep4.1935] [Reference Citation Analysis]
35 Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology 2020;71:907-16. [PMID: 31309602 DOI: 10.1002/hep.30858] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 32.5] [Reference Citation Analysis]
36 Shengir M, Chen T, Guadagno E, Ramanakumar AV, Ghali P, Deschenes M, Wong P, Krishnamurthy S, Sebastiani G. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta-analysis. JGH Open 2021;5:434-45. [PMID: 33860093 DOI: 10.1002/jgh3.12512] [Reference Citation Analysis]
37 Samala N, Desai A, Vilar-Gomez E, Smith ER, Gawrieh S, Kettler CD, Pike F, Chalasani N. Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:2980-2988.e4. [PMID: 32360826 DOI: 10.1016/j.cgh.2020.04.046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Aehling NF, Seehofer D, Berg T. [Liver transplantation - current trends]. Dtsch Med Wochenschr 2020;145:1124-31. [PMID: 32791547 DOI: 10.1055/a-0982-0737] [Reference Citation Analysis]
39 Shah RA, Alkhouri N, Kowdley KV. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. Expert Opinion on Emerging Drugs 2020;25:251-60. [DOI: 10.1080/14728214.2020.1796968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Wang C, Pai AK, Putra J. Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation. J Clin Pathol 2022:jclinpath-2022-208246. [PMID: 35414523 DOI: 10.1136/jclinpath-2022-208246] [Reference Citation Analysis]
41 Dennis A, Kelly MD, Fernandes C, Mouchti S, Fallowfield JA, Hirschfield G, Pavlides M, Harrison S, Chakravarthy MV, Banerjee R, Sanyal A. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2020;11:575843. [PMID: 33584535 DOI: 10.3389/fendo.2020.575843] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Steggerda JA, Mahendraraj K, Todo T, Noureddin M. Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. World J Gastroenterol 2020; 26(28): 4018-4035 [PMID: 32821068 DOI: 10.3748/wjg.v26.i28.4018] [Reference Citation Analysis]
43 Yu Y, Yu L, Cheng N, Liu X, Fang C, Liu S, Zhu L. Exercise Alleviates the Apolipoprotein A5-Toll-Like Receptor 4 Axis Impairment in Mice With High-Fat Diet-Induced Non-alcoholic Steatohepatitis. Front Physiol 2021;12:783341. [PMID: 35035359 DOI: 10.3389/fphys.2021.783341] [Reference Citation Analysis]
44 Martin K, Hatab A, Athwal VS, Jokl E, Piper Hanley K. Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications. Curr Diab Rep 2021;21:8. [PMID: 33544287 DOI: 10.1007/s11892-021-01377-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Rosenblatt R, Atteberry P, Tafesh Z, Ravikumar A, Crawford CV, Lucero C, Jesudian AB, Brown RS Jr, Kumar S, Fortune BE. Uncontrolled diabetes mellitus increases risk of infection in patients with advanced cirrhosis. Dig Liver Dis 2021;53:445-51. [PMID: 33153928 DOI: 10.1016/j.dld.2020.10.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Talens M, Tumas N, Lazarus JV, Benach J, Pericàs JM. What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review. J Clin Med 2021;10:5019. [PMID: 34768539 DOI: 10.3390/jcm10215019] [Reference Citation Analysis]
47 Singh A, Gosai F, Siddiqui MT, Gupta M, Lopez R, Lawitz E, Poordad F, Carey W, McCullough A, Alkhouri N. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol 2020;54:891-7. [PMID: 32168133 DOI: 10.1097/MCG.0000000000001339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
48 Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Shiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ; IDN-6556-14 Investigators(‡). Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol 2020;72:885-95. [PMID: 31870950 DOI: 10.1016/j.jhep.2019.12.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
49 Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, Bouras E, Haidich AB, Papatheodoridis G. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:404-14. [PMID: 33948067 DOI: 10.20524/aog.2021.0604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Phipps M, Livanos A, Guo A, Pomenti S, Yeh J, Dakhoul L, Burney H, Kettler C, Liu H, Miller E, Gawrieh S, deLemos A, Scanga A, Chalasani N, Wattacheril J. Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. Am J Gastroenterol 2020;115:1486-95. [PMID: 32453046 DOI: 10.14309/ajg.0000000000000643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
51 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
52 Chen XY, Wang C, Huang YZ, Zhang LL. Nonalcoholic fatty liver disease shows significant sex dimorphism. World J Clin Cases 2022; 10(5): 1457-1472 [DOI: 10.12998/wjcc.v10.i5.1457] [Reference Citation Analysis]
53 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Lazarus JV, Mark HE, Rinella ME, Colombo M. Editorial: global liver fat accumulation and global health—towards a sustainable development goal. Authors' reply. Aliment Pharmacol Ther 2022;55:489-90. [DOI: 10.1111/apt.16768] [Reference Citation Analysis]
55 Ascher Bartlett JM, Mittal N. Approach to Pediatric Obesity and Nonalcoholic Fatty Liver Disease. Pediatr Ann 2021;50:e474-7. [PMID: 34757877 DOI: 10.3928/19382359-20211019-02] [Reference Citation Analysis]
56 Moore HB, Bababekov YJ, Pomposelli JJ, Adams MA, Crouch C, Yoeli D, Choudhury RA, Ferrell T, Burton JR, Pomfret EA, Nydam TL. The vexing triad of obestiy, alcohol, and coagulopathy predicts the need for multiple operations in liver transplantation. The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.02.053] [Reference Citation Analysis]
57 Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020;12:E2762. [PMID: 32927776 DOI: 10.3390/nu12092762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
58 Softic S, Kohli R. Pediatric NASH therapies: A speedbump on the road to success. Hepatology 2022. [PMID: 35000211 DOI: 10.1002/hep.32322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Alkhouri N, Gawrieh S. A perspective on RNA interference-based therapeutics for metabolic liver diseases. Expert Opin Investig Drugs 2021;30:237-44. [PMID: 33470860 DOI: 10.1080/13543784.2021.1879792] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Sharma P, Sun Y, Neal J, Erley J, Shen J, Tischer S, Sonnenday CJ, Park JM. Renal Outcomes of Liver Transplantation Recipients Receiving Standard Immunosuppression and Early Renal Sparing Immunosuppression: A Retrospective Single Center Study. Transplant Direct 2019;5:e480. [PMID: 31579808 DOI: 10.1097/TXD.0000000000000917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 van Dijk AM, Dingerink S, Chilunga FP, Meeks KAC, Bahendeka S, Schulze MB, Danquah I, Osei TB, Serné E, Agyemang C, Holleboom AG. Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations. J Clin Transl Hepatol 2021;9:494-502. [PMID: 34447678 DOI: 10.14218/JCTH.2021.00066] [Reference Citation Analysis]
62 Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, Ahmed A, Racila A, Henry L. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19:580-589.e5. [PMID: 32531342 DOI: 10.1016/j.cgh.2020.05.064] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
63 Enooku K, Nakagawa H, Fujiwara N, Kondo M, Minami T, Hoshida Y, Shibahara J, Tateishi R, Koike K. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Sci Rep 2019;9:10663. [PMID: 31337855 DOI: 10.1038/s41598-019-47216-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
64 Nagaoka K, Mulla J, Cao K, Cheng Z, Liu D, William Mueller, Bay A, Hildebrand G, Lu S, Huang C. The metabolite, alpha-ketoglutarate inhibits non-alcoholic fatty liver disease progression by targeting lipid metabolism. Liver Research 2020;4:94-100. [DOI: 10.1016/j.livres.2020.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
65 Reddy YK, Marella HK, Jiang Y, Ganguli S, Snell P, Podila PSB, Maliakkal B, Satapathy SK. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. J Clin Exp Hepatol. 2020;10:245-254. [PMID: 32405181 DOI: 10.1016/j.jceh.2019.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Alkhouri N, Lawitz E, Noureddin M. Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment. Hepatol Commun 2019;3:605-13. [PMID: 31061949 DOI: 10.1002/hep4.1342] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
68 Pai RK, Kleiner DE, Hart J, Adeyi OA, Clouston AD, Behling CA, Jain D, Kakar S, Brahmania M, Burgart L, Batts KP, Valasek MA, Torbenson MS, Guindi M, Wang HL, Ajmera V, Adams LA, Parker CE, Feagan BG, Loomba R, Jairath V. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther 2019;50:1100-11. [PMID: 31583739 DOI: 10.1111/apt.15503] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
69 Goldberg DS, Vianna RM, Martin EF, Martin P, Arosemena Benitez LR, O’brien CB, Bhamidimarri KR. Simultaneous Liver Kidney Transplant in Elderly Patients With Chronic Kidney Disease: Is There an Appropriate Upper Age Cutoff? Transplantation 2020;104:2538-46. [DOI: 10.1097/tp.0000000000003147] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
70 Are VS, Knapp SM, Banerjee A, Shamseddeen H, Ghabril M, Orman E, Patidar KR, Chalasani N, Desai AP. Improving Outcomes of Bariatric Surgery in Patients With Cirrhosis in the United States: A Nationwide Assessment. Am J Gastroenterol 2020;115:1849-56. [PMID: 33156104 DOI: 10.14309/ajg.0000000000000911] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, Sebastiani G. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World J Gastroenterol 2020; 26(44): 7046-7060 [PMID: 33311949 DOI: 10.3748/wjg.v26.i44.7046] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Alberti G, Gana JC, Santos JL. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E3531. [PMID: 33212947 DOI: 10.3390/nu12113531] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Gilad O, Rabinowich L, Levy S, Gotlieb N, Lubezky N, Goykhman Y, Nachmany I, Katz P, Shibolet O, Katchman H. Metabolic and Renal Effects of Mammalian Target of Rapamycin Inhibitors Treatment After Liver Transplantation: Real-Life Single-Center Experience. Transplant Proc 2021;53:221-7. [PMID: 32650991 DOI: 10.1016/j.transproceed.2020.05.021] [Reference Citation Analysis]
75 Sebastiani G, Patel K, Ratziu V, Feld JJ, Neuschwander-tetri BA, Pinzani M, Petta S, Berzigotti A, Metrakos P, Shoukry N, Brunt EM, Tang A, Cobbold JF, Ekoe J, Seto K, Ghali P, Chevalier S, Anstee QM, Watson H, Bajaj H, Stone J, Swain MG, Ramji A. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). CanLivJ 2022;5:61-90. [DOI: 10.3138/canlivj-2021-0030] [Reference Citation Analysis]
76 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
77 Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemp Clin Trials 2020;89:105922. [PMID: 31881392 DOI: 10.1016/j.cct.2019.105922] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
78 Lin H, Bai Z, Guo X, Qi X. Association between nonalcoholic fatty liver disease and portal vein thrombosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:1405-6. [PMID: 32858662 DOI: 10.1097/MEG.0000000000001689] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Tejedor M, Selzner N, Berenguer M. Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List? Transplantation 2022. [PMID: 35594480 DOI: 10.1097/TP.0000000000004163] [Reference Citation Analysis]
80 Yuan L, Kardashian A, Sarkar M. NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities. Curr Hepatol Rep 2019;18:425-32. [PMID: 32523869 DOI: 10.1007/s11901-019-00495-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Geier A, Rinella ME, Balp MM, McKenna SJ, Brass CA, Przybysz R, Cai J, Knight A, Gavaghan M, Howe T, Rosen D, Ratziu V. Real-World Burden of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2021;19:1020-1029.e7. [PMID: 32634622 DOI: 10.1016/j.cgh.2020.06.064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Hou X, Guan Y, Tang Y, Song A, Zhao J, Ren L, Chen S, Wei L, Ma H, Song G. A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test. Lipids Health Dis 2021;20:54. [PMID: 34034748 DOI: 10.1186/s12944-021-01483-z] [Reference Citation Analysis]
83 Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology 2019;70:1521-30. [PMID: 31271665 DOI: 10.1002/hep.30842] [Cited by in Crossref: 123] [Cited by in F6Publishing: 95] [Article Influence: 41.0] [Reference Citation Analysis]
84 Nephew LD, Serper M. Racial, Gender, and Socioeconomic Disparities in Liver Transplantation. Liver Transpl 2021;27:900-12. [PMID: 33492795 DOI: 10.1002/lt.25996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
86 Rahman MM, Kibria MG, Begum H, Haque M, Sultana N, Akhter M, Rowshon AHM, Ahmed F, Hasan M. Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia. BMJ Open Gastroenterol 2020;7:e000535. [PMID: 33376110 DOI: 10.1136/bmjgast-2020-000535] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Ding L, Oligschlaeger Y, Shiri-Sverdlov R, Houben T. Nonalcoholic Fatty Liver Disease. Handb Exp Pharmacol 2020. [PMID: 32185502 DOI: 10.1007/164_2020_352] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019;16:517-30. [DOI: 10.1038/s41575-019-0169-z] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 21.7] [Reference Citation Analysis]
89 Thylur RP, Roy SK, Shrivastava A, LaVeist TA, Shankar S, Srivastava RK. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open 2020;4:351-9. [PMID: 32514436 DOI: 10.1002/jgh3.12336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
90 Brandman D. Obesity Management of Liver Transplant Waitlist Candidates and Recipients. Clin Liver Dis 2021;25:1-18. [PMID: 33978572 DOI: 10.1016/j.cld.2020.08.001] [Reference Citation Analysis]
91 Shavelle RM, Saur RC, Kwak JH, Brooks JC, Hameed B. Life Expectancy after Liver Transplantation for NASH. Prog Transpl. [DOI: 10.1177/15269248221087441] [Reference Citation Analysis]
92 Stine JG, Schreibman I, Navabi S, Kang M, Dahmus J, Soriano C, Rivas G, Hummer B, Beyer M, Tressler H, Kimball SR, Patterson AD, Schmitz K, Sciamanna C. Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH. Contemp Clin Trials Commun 2020;18:100560. [PMID: 32309672 DOI: 10.1016/j.conctc.2020.100560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
93 Wang L, Zhang X, Lin ZB, Yang PJ, Xu H, Duan JL, Ruan B, Song P, Liu JJ, Yue ZS, Fang ZQ, Hu H, Liu Z, Huang XL, Yang L, Tian S, Tao KS, Han H, Dou KF. Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1. Cell Metab 2021;33:1372-1388.e7. [PMID: 34146477 DOI: 10.1016/j.cmet.2021.05.019] [Reference Citation Analysis]
94 Hirode G, Vittinghoff E, Wong RJ. Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample. Dig Dis Sci 2019;64:1448-57. [PMID: 30863953 DOI: 10.1007/s10620-019-05576-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
95 Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:947-55. [PMID: 32780094 DOI: 10.1093/ibd/izaa189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
96 Jothimani D, Danielraj S, Narasimhan G, Kaliamoorthy I, Rajakumar A, Palaniappan K, Palanichamy S, Rammohan A, Ramachandran H, Rajalingam R, Rela M. Nonalcoholic Steatohepatitis: A Rapidly Increasing Indication for Liver Transplantation in India. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.09.017] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Trivedi HD, Suri J, Oh D, Schwartz J, Goyes D, Idriss R, Curry MP, Lai M. The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. Ann Hepatol 2021;24:100336. [PMID: 33647502 DOI: 10.1016/j.aohep.2021.100336] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Burchill MA, Finlon JM, Goldberg AR, Gillen AE, Dahms PA, McMahan RH, Tye A, Winter AB, Reisz JA, Bohrnsen E, Schafer JB, D'Alessandro A, Orlicky DJ, Kriss MS, Rosen HR, McCullough RL, Jirón Tamburini BA. Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System. Cell Mol Gastroenterol Hepatol 2021;11:573-95. [PMID: 32961356 DOI: 10.1016/j.jcmgh.2020.09.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
99 Alkhouri N, Tincopa M, Loomba R, Harrison SA. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? Hepatol Commun 2021;5:1810-23. [PMID: 34499435 DOI: 10.1002/hep4.1814] [Reference Citation Analysis]
100 Samji NS, Verma R, Satapathy SK. Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. J Clin Exp Hepatol 2019;9:497-505. [PMID: 31516266 DOI: 10.1016/j.jceh.2019.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
101 Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, Magini G, Frossard JL, Bascaron ME, Vernaz N, Zampaglione L, Negro F, Goossens N. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep 2021;3:100231. [PMID: 33748726 DOI: 10.1016/j.jhepr.2021.100231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
102 Sarkar M, Grab J, Dodge JL, Gunderson EP, Rubin J, Irani RA, Cedars M, Terrault N. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J Hepatol 2020;73:516-22. [PMID: 32531415 DOI: 10.1016/j.jhep.2020.03.049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
103 Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2021:S0168-8278(21)02177-2. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Reference Citation Analysis]
104 Villani R, Magnati GP, De Girolamo G, Sangineto M, Romano AD, Cassano T, Serviddio G. Genetic Polymorphisms and Clinical Features in Diabetic Patients With Fatty Liver: Results From a Single-Center Experience in Southern Italy. Front Med (Lausanne) 2021;8:737759. [PMID: 34746177 DOI: 10.3389/fmed.2021.737759] [Reference Citation Analysis]
105 Nier A, Huber Y, Labenz C, Michel M, Bergheim I, Schattenberg JM. Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E699. [PMID: 32151020 DOI: 10.3390/nu12030699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
106 Smiderle CA, Coral GP, DE Carli LA, Mattos AA, Mattos AZ, Tovo CV. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS. Arq Gastroenterol 2021;58:139-44. [PMID: 34231659 DOI: 10.1590/S0004-2803.202100000-24] [Reference Citation Analysis]
107 Loomba R, Adams LA. The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH. Hepatology 2019;70:1885-8. [PMID: 31520407 DOI: 10.1002/hep.30946] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
108 Koutoukidis DA, Astbury NM, Tudor KE, Morris E, Henry JA, Noreik M, Jebb SA, Aveyard P. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019;. [PMID: 31260026 DOI: 10.1001/jamainternmed.2019.2248] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 23.0] [Reference Citation Analysis]
109 Vieira Barbosa J, Lai M. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. Hepatol Commun 2021;5:158-67. [PMID: 33553966 DOI: 10.1002/hep4.1618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
110 Younossi ZM, Henry L. Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH). Endocr Pract 2021:S1530-891X(21)01417-8. [PMID: 34952219 DOI: 10.1016/j.eprac.2021.12.010] [Reference Citation Analysis]
111 Bhat M, Usmani SE, Azhie A, Woo M. Metabolic Consequences of Solid Organ Transplantation. Endocr Rev 2021;42:171-97. [PMID: 33247713 DOI: 10.1210/endrev/bnaa030] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3 and STELLAR-4 Investigators. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73:26-39. [PMID: 32147362 DOI: 10.1016/j.jhep.2020.02.027] [Cited by in Crossref: 86] [Cited by in F6Publishing: 94] [Article Influence: 43.0] [Reference Citation Analysis]
113 Sarkar MA, Suzuki A, Abdelmalek MF, Yates KP, Wilson LA, Bass NM, Gill R, Cedars M, Terrault N; NASH Clinical Research Network. Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD. Clin Gastroenterol Hepatol 2021;19:1267-1274.e1. [PMID: 33010412 DOI: 10.1016/j.cgh.2020.09.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Im GY, Cameron AM, Lucey MR. Liver transplantation for alcoholic hepatitis. J Hepatol 2019;70:328-34. [PMID: 30658734 DOI: 10.1016/j.jhep.2018.11.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 24.0] [Reference Citation Analysis]
116 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
117 Singal AK, Arora S, Wong RJ, Satapathy SK, Shah VH, Kuo YF, Kamath PS. Increasing Burden of Acute-On-Chronic Liver Failure Among Alcohol-Associated Liver Disease in the Young Population in the United States. Am J Gastroenterol. 2020;115:88-95. [PMID: 31651447 DOI: 10.14309/ajg.0000000000000411] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
118 Tamburini BAJ, Finlon JM, Gillen AE, Kriss MS, Riemondy KA, Fu R, Schuyler RP, Hesselberth JR, Rosen HR, Burchill MA. Chronic Liver Disease in Humans Causes Expansion and Differentiation of Liver Lymphatic Endothelial Cells. Front Immunol 2019;10:1036. [PMID: 31156626 DOI: 10.3389/fimmu.2019.01036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
119 Tang G, Xu Y, Zhang C, Wang N, Li H, Feng Y. Green Tea and Epigallocatechin Gallate (EGCG) for the Management of Nonalcoholic Fatty Liver Diseases (NAFLD): Insights into the Role of Oxidative Stress and Antioxidant Mechanism. Antioxidants (Basel) 2021;10:1076. [PMID: 34356308 DOI: 10.3390/antiox10071076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Li T, Chen Y, Tan P, Shi H, Huang Z, Cai T, Cheng Y, Du Y, Fu W. Dihydroartemisinin alleviates steatosis and inflammation in nonalcoholic steatohepatitis by decreasing endoplasmic reticulum stress and oxidative stress. Bioorg Chem 2022;122:105737. [PMID: 35338970 DOI: 10.1016/j.bioorg.2022.105737] [Reference Citation Analysis]
121 Noureddin M, Sanyal AJ. Pathogenesis of NASH: The Impact of Multiple Pathways. Curr Hepatol Rep 2018;17:350-60. [PMID: 31380156 DOI: 10.1007/s11901-018-0425-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
122 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA 2020;323:1175-83. [PMID: 32207804 DOI: 10.1001/jama.2020.2298] [Cited by in Crossref: 267] [Cited by in F6Publishing: 210] [Article Influence: 133.5] [Reference Citation Analysis]
124 Liang C, Li J, Tian B, Tian L, Liu Y, Li J, Xin L, Wang J, Fu C, Shi Z, Xia J, Liang Y, Wang K. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment. Biomed Pharmacother 2021;144:112298. [PMID: 34649219 DOI: 10.1016/j.biopha.2021.112298] [Reference Citation Analysis]
125 Thiagarajan P, Aithal GP. Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. J Clin Exp Hepatol 2019;9:515-21. [PMID: 31516268 DOI: 10.1016/j.jceh.2019.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
126 Diaz Soto MP, Lim JK. Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data. Hepat Med 2020;12:115-23. [PMID: 32884369 DOI: 10.2147/HMER.S230613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
127 Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9. [PMID: 32518675 DOI: 10.1186/s40842-020-00097-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
128 Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 2020;29:135-41. [PMID: 31519114 DOI: 10.1080/13543784.2020.1668374] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
129 DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology 2020;161:bqaa134. [PMID: 32776116 DOI: 10.1210/endocr/bqaa134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
130 Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389-398. [PMID: 30902670 DOI: 10.1016/s2468-1253(19)30039-1] [Cited by in Crossref: 165] [Cited by in F6Publishing: 94] [Article Influence: 55.0] [Reference Citation Analysis]
131 Armstrong LE, Guo GL. Understanding Environmental Contaminants' Direct Effects on Non-alcoholic Fatty Liver Disease Progression. Curr Environ Health Rep 2019;6:95-104. [PMID: 31090041 DOI: 10.1007/s40572-019-00231-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
132 Watanabe M, Tuccinardi D, Ernesti I, Basciani S, Mariani S, Genco A, Manfrini S, Lubrano C, Gnessi L. Scientific evidence underlying contraindications to the ketogenic diet: An update. Obes Rev 2020;21:e13053. [PMID: 32648647 DOI: 10.1111/obr.13053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
133 Doycheva I, Ehrmann DA. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril 2022;117:897-911. [PMID: 35512974 DOI: 10.1016/j.fertnstert.2022.03.020] [Reference Citation Analysis]
134 Machado MV. Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:3627-45. [PMID: 34408459 DOI: 10.2147/DMSO.S304357] [Reference Citation Analysis]
135 Jamal M, AlMahmeed H, AlGhanem M, AlMatooq M, Sadek A, AlMousawi M, Al-Sabah S, Vilca Melendez H, Rela M, Heaton N, Jassem W. Organ Transplantation in Kuwait and the Recent Initiation of a Liver Program. Transplantation 2021;105:2125-7. [PMID: 34591813 DOI: 10.1097/TP.0000000000003537] [Reference Citation Analysis]
136 Altshuler PJ, Dang H, Frank AM, Shah AP, Glorioso J, Zhan T, Rios Diaz A, Shaheen O, Ramirez CB, Maley WR, Bodzin AS. Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allografts and Nonalcoholic Steatohepatitis. Liver Transpl 2021. [PMID: 34564931 DOI: 10.1002/lt.26313] [Reference Citation Analysis]
137 Wegermann K, Garrett ME, Zheng J, Coviello A, Moylan CA, Abdelmalek MF, Chow SC, Guy CD, Diehl AM, Ashley-Koch A, Suzuki A. Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD. Hepatol Commun 2021;5:598-607. [PMID: 33860118 DOI: 10.1002/hep4.1668] [Reference Citation Analysis]
138 Lao TT. Implications of abnormal liver function in pregnancy and non-alcoholic fatty liver disease. Best Pract Res Clin Obstet Gynaecol 2020;68:2-11. [PMID: 32312689 DOI: 10.1016/j.bpobgyn.2020.02.011] [Reference Citation Analysis]
139 McCabe P, Hirode G, Wong R. Functional Status at Liver Transplant Waitlisting Correlates With Greater Odds of Encephalopathy, Ascites, and Spontaneous Bacterial Peritonitis. J Clin Exp Hepatol 2020;10:413-20. [PMID: 33029049 DOI: 10.1016/j.jceh.2020.04.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Brown SA, Izzy M, Watt KD. Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. Hepatology 2021;73:2051-62. [PMID: 33047343 DOI: 10.1002/hep.31595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Hunter AK, Lin HC. Review of Clinical Guidelines in the Diagnosis of Pediatric Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2021;18:40-4. [PMID: 34484704 DOI: 10.1002/cld.1094] [Reference Citation Analysis]
142 Watanabe M, Tozzi R, Risi R, Tuccinardi D, Mariani S, Basciani S, Spera G, Lubrano C, Gnessi L. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: A comprehensive review of the literature. Obes Rev 2020;21:e13024. [PMID: 32207237 DOI: 10.1111/obr.13024] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 18.0] [Reference Citation Analysis]
143 Chayanupatkul M, Dasani DB, Sogaard K, Schiano TD. The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter. Transplant Proc. 2020;. [PMID: 32434740 DOI: 10.1016/j.transproceed.2020.02.160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
144 Noureddin N, Schattenberg JM, Alkhouri N, Noureddin M. Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass? Hepatol Commun 2020;4:141-4. [PMID: 32025600 DOI: 10.1002/hep4.1473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
145 Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, Clement S, Basu R, Gordon SC, Ravendhra N, Puri P, Rinella M, Scudera P, Singal AK, Henry L; US Members of the Global Nash Council. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.Aliment Pharmacol Ther. 2020;52:513-526. [PMID: 32598051 DOI: 10.1111/apt.15830] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
146 Mato JM, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(24): 3009-3020 [PMID: 31293337 DOI: 10.3748/wjg.v25.i24.3009] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
147 Musto J, Spengler EK, German MN. Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2021;20:97-107. [DOI: 10.1007/s11901-021-00568-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Slaughter VL, Rumsey JW, Boone R, Malik D, Cai Y, Sriram NN, Long CJ, McAleer CW, Lambert S, Shuler ML, Hickman JJ. Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation. Sci Rep 2021;11:13159. [PMID: 34162924 DOI: 10.1038/s41598-021-92264-2] [Reference Citation Analysis]
149 Samji NS, Heda R, Kovalic AJ, Satapathy SK. Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. Gastroenterology Clinics of North America 2020;49:151-64. [DOI: 10.1016/j.gtc.2019.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Kutzler HL, Peters J, O’sullivan DM, Williamson A, Cheema F, Ebcioglu Z, Einstein M, Rochon C, Ye X, Sheiner P, Singh JU, Sotil EU, Swales C, Serrano OK. Disparities in End-Organ Care for Hispanic Patients with Kidney and Liver Disease: Implications for Access to Transplantation. Curr Surg Rep 2020;8. [DOI: 10.1007/s40137-020-00248-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Holm Damgaard L, Buchholtz K, Skalshøi Kjær M, Balendran C, Myers RP, Loomba R, Noureddin M. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.003] [Reference Citation Analysis]
152 Younossi ZM, Wong VW, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. Hepatol Commun 2020;4:1637-50. [PMID: 33163834 DOI: 10.1002/hep4.1581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
153 Kim I, Seo S. Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report. Clin Pharmacol Ther 2021;109:292-4. [PMID: 32740920 DOI: 10.1002/cpt.1978] [Reference Citation Analysis]
154 Sobotka LA, Mumtaz K, Wellner MR, Kelly SG, Conteh LF, Hanje AJ, Schenk A, El-Hinnawi A, Black S, Washburn K, Pesavento T, Daloul R, Michaels AJ. Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: A large single center analysis. Ann Hepatol 2021;24:100318. [PMID: 33515801 DOI: 10.1016/j.aohep.2021.100318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
155 de Avila V, Paik JM, de Avila L, Henry L, Mohess D, Roche-Green A, Younossi ZM. Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States. JHEP Rep 2021;3:100236. [PMID: 33748729 DOI: 10.1016/j.jhepr.2021.100236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Gill MG, Majumdar A. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World J Hepatol 2020; 12(12): 1168-1181 [PMID: 33442446 DOI: 10.4254/wjh.v12.i12.1168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Steggerda JA, Noureddin N, Alkhouri N, Todo T, Dong Yang J, Kim IK, Noureddin M. Sex differences in age at wait-list registration for liver transplantation with nonalcoholic steatohepatitis as primary indication. Clin Transplant 2021;35:e14163. [PMID: 33280172 DOI: 10.1111/ctr.14163] [Reference Citation Analysis]
158 Chalasani N, Abdelmalek MF, Garcia-tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, Allgood A, Shlevin H, Horton R, Zomer E, Irish W, Goodman Z, Harrison SA, Traber PG, Abdelmalek M, Balart L, Borg B, Chalasani N, Charlton M, Conjeevaram H, Fuchs M, Ghalib R, Gholam P, Halegoua-de Marzio D, Harrison S, Jue C, Kemmer N, Kowdley K, Lai M, Lawitz E, Loomba R, Noureddin M, Paredes A, Rinella M, Rockey D, Rodriguez M, Rubin R, Ryan M, Sanyal A, Scanga A, Sepe T, Shiffman M, Shiffman M, Tetri B, Thuluvath P, Torres D, Vierling J, Wattacheril J, Weiland A, Zogg D. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology 2020;158:1334-1345.e5. [DOI: 10.1053/j.gastro.2019.11.296] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 30.5] [Reference Citation Analysis]
159 Gassenmaier S, Kähm K, Walter SS, Machann J, Nikolaou K, Bongers MN. Quantification of liver and muscular fat using contrast-enhanced Dual Source Dual Energy Computed Tomography compared to an established multi-echo Dixon MRI sequence. Eur J Radiol 2021;142:109845. [PMID: 34271430 DOI: 10.1016/j.ejrad.2021.109845] [Reference Citation Analysis]
160 Hansen HH, Ægidius HM, Oró D, Evers SS, Heebøll S, Eriksen PL, Thomsen KL, Bengtsson A, Veidal SS, Feigh M, Suppli MP, Knop FK, Grønbæk H, Miranda D, Trevaskis JL, Vrang N, Jelsing J, Rigbolt KTG. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020;20:210. [PMID: 32631250 DOI: 10.1186/s12876-020-01356-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
161 Noureddin M, Truong E, Gornbein JA, Saouaf R, Guindi M, Todo T, Noureddin N, Yang JD, Harrison SA, Alkhouri N. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol 2021:S0168-8278(21)02184-X. [PMID: 34798176 DOI: 10.1016/j.jhep.2021.11.012] [Reference Citation Analysis]
162 Brancaccio G, Vitale A, Signoriello G, Gaeta GB, Cillo U. Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. Infect Dis (Lond) 2020;52:557-62. [PMID: 32401092 DOI: 10.1080/23744235.2020.1763453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 2020;71:306-33. [PMID: 31314133 DOI: 10.1002/hep.30866] [Cited by in Crossref: 199] [Cited by in F6Publishing: 154] [Article Influence: 99.5] [Reference Citation Analysis]
164 Majumdar A, Verbeek J, Tsochatzis EA. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol 2021;61:98-105. [PMID: 34688168 DOI: 10.1016/j.coph.2021.09.007] [Reference Citation Analysis]
165 Izzy M, Angirekula M, Abu Dayyeh BK, Bazerbachi F, Watt KD. Bariatric surgery proves long-term benefit in patients with cirrhosis. Gastroenterol Rep (Oxf) 2021;9:252-6. [PMID: 34316375 DOI: 10.1093/gastro/goaa057] [Reference Citation Analysis]
166 Kaufmann B, Reca A, Wang B, Friess H, Feldstein AE, Hartmann D. Mechanisms of nonalcoholic fatty liver disease and implications for surgery. Langenbecks Arch Surg 2021;406:1-17. [PMID: 32833053 DOI: 10.1007/s00423-020-01965-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
168 Sharma D, Gotlieb N, Farkouh ME, Patel K, Xu W, Bhat M. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort. J Am Heart Assoc 2021;:e022576. [PMID: 34927450 DOI: 10.1161/JAHA.121.022576] [Reference Citation Analysis]
169 Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract 2020;35:72-84. [PMID: 31840865 DOI: 10.1002/ncp.10449] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
170 Zhu K, Guo Y, Zhao C, Kang S, Li J, Wang J, Tang Z, Lin B, Li W. Etiology Exploration of Non-alcoholic Fatty Liver Disease From Traditional Chinese Medicine Constitution Perspective: A Cross-Sectional Study. Front Public Health 2021;9:635818. [PMID: 34055713 DOI: 10.3389/fpubh.2021.635818] [Reference Citation Analysis]
171 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019; 25(29): 3929-3940 [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
172 Goldner D, Lavine JE. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology. 2020;158:1967-1983.e1. [PMID: 32201176 DOI: 10.1053/j.gastro.2020.01.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
173 Alkhouri N, Reddy GK, Lawitz E. Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases. Hepatology 2021;73:1581-93. [PMID: 32978989 DOI: 10.1002/hep.31569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
174 Harrison SA, Calanna S, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal A, Sejling AS, Newsome PN. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. Contemp Clin Trials 2020;97:106174. [PMID: 33039693 DOI: 10.1016/j.cct.2020.106174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
175 Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology 2019;70:1457-69. [PMID: 30924946 DOI: 10.1002/hep.30626] [Cited by in Crossref: 261] [Cited by in F6Publishing: 215] [Article Influence: 87.0] [Reference Citation Analysis]
176 Zhou YJ, Gao F, Liu WY, Wong GL, Mahadeva S, Raihan Nik Mustapha N, Wang XD, Chan WK, Wong VW, Zheng MH. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2021;54:470-80. [PMID: 34152626 DOI: 10.1111/apt.16487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
177 A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. In: Hamdy Gad E, editor. Nonalcoholic Fatty Liver Disease - An Update. IntechOpen; 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Albhaisi S, Noureddin M. Current and Potential Therapies Targeting Inflammation in NASH. Front Endocrinol (Lausanne) 2021;12:767314. [PMID: 34925237 DOI: 10.3389/fendo.2021.767314] [Reference Citation Analysis]
179 Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol 2021; 27(17): 1864-1882 [PMID: 34007127 DOI: 10.3748/wjg.v27.i17.1864] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Aggarwal P, Noureddin M, Harrison S, Jeannin S, Alkhouri N. Nonalcoholic steatohepatitis (NASH) cirrhosis: A snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032640] [Reference Citation Analysis]
181 Trivedi HD, Lopes EW, Glissen Brown J, Dudani S, Lai M, Feuerstein JD, Pierce TT. Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-analysis. J Clin Gastroenterol 2022. [PMID: 35648974 DOI: 10.1097/MCG.0000000000001727] [Reference Citation Analysis]
182 Molinari M, Fernandez-Carrillo C, Dai D, Dana J, Clemente-Sanchez A, Dharmayan S, Kaltenmeier C, Liu H, Behari J, Rachakonda V, Ganesh S, Hughes C, Tevar A, Al Harakeh H, Emmanuel B, Humar A, Bataller R. Portal vein thrombosis and renal dysfunction: a national comparative study of liver transplant recipients for NAFLD versus alcoholic cirrhosis. Transpl Int 2021;34:1105-22. [PMID: 33780554 DOI: 10.1111/tri.13873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Hsu MJ, Karkossa I, Schäfer I, Christ M, Kühne H, Schubert K, Rolle-Kampczyk UE, Kalkhof S, Nickel S, Seibel P, von Bergen M, Christ B. Mitochondrial Transfer by Human Mesenchymal Stromal Cells Ameliorates Hepatocyte Lipid Load in a Mouse Model of NASH. Biomedicines 2020;8:E350. [PMID: 32937969 DOI: 10.3390/biomedicines8090350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
184 Rivas G, Hummer-Bair B, Bezinover D, Kadry Z, Stine J. Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis. BMJ Open Gastroenterol 2021;8:e000683. [PMID: 34341018 DOI: 10.1136/bmjgast-2021-000683] [Reference Citation Analysis]
185 Roeb E. Non-alcoholic fatty liver diseases: current challenges and future directions. Ann Transl Med 2021;9:726. [PMID: 33987424 DOI: 10.21037/atm-20-3760] [Reference Citation Analysis]
186 Yska HAF, Khen-Dunlop N, Lacaille F, Dabbas M. Long-Term Results of Laparoscopic Adjustable Gastric Banding in French adolescents: The Utmost Importance of Follow-Up. J Pediatr Gastroenterol Nutr 2021;72:906-11. [PMID: 33720097 DOI: 10.1097/MPG.0000000000003092] [Reference Citation Analysis]
187 Singh A, Amin H, Garg R, Gupta M, Lopez R, Alkhouri N, Mccullough A. Increased Prevalence of Obesity and Metabolic Syndrome in Patients with Alcoholic Fatty Liver Disease. Dig Dis Sci 2020;65:3341-9. [DOI: 10.1007/s10620-020-06056-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
188 Wang S, Toy M, Hang Pham TT, So S. Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019. PLoS One 2020;15:e0239393. [PMID: 32946502 DOI: 10.1371/journal.pone.0239393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
189 Gaballa D, Bezinover D, Kadry Z, Eyster E, Wang M, Northup PG, Stine JG. Development of a Model to Predict Portal Vein Thrombosis in Liver Transplant Candidates: The Portal Vein Thrombosis Risk Index. Liver Transpl 2019;25:1747-55. [PMID: 31436367 DOI: 10.1002/lt.25630] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
190 Allen BJW, Abu Shanab AA, Anderson MR, Fogden EN. Recurrent Pyroglutamic Acidosis in the Context of Undiagnosed Liver Cirrhosis-A Case Report. J Clin Exp Hepatol 2021;11:623-7. [PMID: 34511825 DOI: 10.1016/j.jceh.2020.10.004] [Reference Citation Analysis]
191 Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
192 McHenry S, Park Y, Browning JD, Sayuk G, Davidson NO. Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:2073-2080.e7. [PMID: 31982611 DOI: 10.1016/j.cgh.2020.01.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
193 Da BL, Surana P, Schueler SA, Jalaly NY, Kamal N, Taneja S, Vittal A, Gilman CL, Heller T, Koh C. Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease. Hepatol Commun 2019;3:1271-80. [PMID: 31497747 DOI: 10.1002/hep4.1394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
194 Stine JG, Xu D, Schmitz K, Sciamanna C, Kimball SR. Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease. Dig Dis Sci 2020;65:3238-43. [PMID: 32239376 DOI: 10.1007/s10620-020-06226-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
195 Kaur N, Emamaullee J, Lian T, Lo M, Ender P, Kahn J, Sher L. Impact of Morbid Obesity on Liver Transplant Candidacy and Outcomes: National and Regional Trends. Transplantation 2021;105:1052-60. [PMID: 33741845 DOI: 10.1097/TP.0000000000003404] [Reference Citation Analysis]
196 Mikulic D, Mrzljak A. Liver transplantation and aging. World J Transplant 2020; 10(9): 256-266 [PMID: 32995320 DOI: 10.5500/wjt.v10.i9.256] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Jiang DD, Roayaie K, Woodland D, Orloff S, Scott D. Survival and renal function after liver transplantation alone in patients meeting the new United Network for Organ Sharing simultaneous liver‐kidney criteria. Clin Transplant 2020;34. [DOI: 10.1111/ctr.14020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
198 Han MAT, Vipani A, Noureddin N, Ramirez K, Gornbein J, Saouaf R, Baniesh N, Cummings-John O, Okubote T, Setiawan VW, Rotman Y, Loomba R, Alkhouri N, Noureddin M. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. Liver Int 2020;40:2242-51. [PMID: 32652744 DOI: 10.1111/liv.14593] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
199 Noureddin M, Chan JL, Barradas K, Dimick-Santos L, Schabel E, Omokaro SO, Anania FA, Myers RP, Miller V, Sanyal AJ, Chalasani N; Liver Forum NASH Cirrhosis Working Group. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. Gastroenterology 2020;159:422-427.e1. [PMID: 32353369 DOI: 10.1053/j.gastro.2020.04.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
200 Natarajan Y, Loomba R. Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD. Journal of Clinical and Experimental Hepatology 2022;12:174-9. [DOI: 10.1016/j.jceh.2021.08.002] [Reference Citation Analysis]
201 Alvarez CS, Graubard BI, Thistle JE, Petrick JL, McGlynn KA. Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow-up. Hepatology 2020;72:430-40. [PMID: 31733165 DOI: 10.1002/hep.31040] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
202 Bae JS, Lee DH, Lee JY, Kim H, Yu SJ, Lee JH, Cho EJ, Lee YB, Han JK, Choi BI. Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique. Eur Radiol. 2019;. [PMID: 31175413 DOI: 10.1007/s00330-019-06272-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
203 Sayiner M, Arshad T, Golabi P, Paik J, Farhat F, Younossi ZM. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. Hepatol Int 2020;14:556-66. [DOI: 10.1007/s12072-020-10038-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
204 Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, Magnanensi J, Hajji Y, Brozek J, Roudot A, Staels B, Hum DW, Megnien SJ, Hosmane S, Dam N, Chaumat P, Hanf R, Anstee QM, Sanyal AJ. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:970-85. [PMID: 32763196 DOI: 10.1016/S2468-1253(20)30252-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
205 Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G; SHIVER Network. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology 2020;71:1831-44. [PMID: 32052857 DOI: 10.1002/hep.31177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
206 Ritchie M, Hanouneh IA, Noureddin M, Rolph T, Alkhouri N. Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? Expert Opin Investig Drugs 2020;29:197-204. [PMID: 31948295 DOI: 10.1080/13543784.2020.1718104] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
207 Samji NS, Verma R, Keri KC, Singal AK, Ahmed A, Rinella M, Bernstein D, Abdelmalek MF, Satapathy SK. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci 2019;64:3413-30. [PMID: 31312990 DOI: 10.1007/s10620-019-05716-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
208 Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, Noureddin M, Carey W, Mccullough A, Alkhouri N. Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort. Dig Dis Sci 2020;65:978-86. [DOI: 10.1007/s10620-019-05700-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
209 Samji NS, Heda R, Satapathy SK. Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates . Transl Gastroenterol Hepatol 2020;5:10. [PMID: 32190778 DOI: 10.21037/tgh.2019.09.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
210 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
211 Alkhouri N, Kohli R, Feldstein AE. Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints. Hepatol Commun 2019;3:1563-70. [PMID: 31832567 DOI: 10.1002/hep4.1449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
212 Frank J, Kisters K, Stirban OA, Obeid R, Lorkowski S, Wallert M, Egert S, Podszun MC, Eckert GP, Pettersen JA, Venturelli S, Classen HG, Golombek J. The role of biofactors in the prevention and treatment of age-related diseases. Biofactors 2021;47:522-50. [PMID: 33772908 DOI: 10.1002/biof.1728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]